Clinical Trial Update: Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma. [Phase 2]

View source ↗

Summary

Phase 2 trial assessing two doses of QVM149 versus salmeterol/fluticasone fixed-dose in asthma; results completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• QVM149 (Indacaterol acetate / glycopyrronium bromide / mometasone furoate)
• Salmeterol/Fluticasone fixed-dose combination (salmeterol/fluticasone)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2019-12-13